{"query-id": "1", "query-text": "Liposarcoma CDK4 Amplification 38-year-old male GERD", "response": "Amplification of CDK4 in liposarcoma is commonly found in older males, including a 38-year-old male with GERD (gastroesophageal reflux disease). This mutation can lead to uncontrolled cell growth and may be associated with aggressive disease.", "metadata": {"model": "llama"}}
{"query-id": "2", "query-text": "Colon cancer KRAS (G13D), BRAF (V600E) 52-year-old male Type II Diabetes, Hypertension", "response": "The KRAS (G13D) and BRAF (V600E) mutations in colon cancer are unlikely to impact the patient's prognosis significantly, due to the presence of other medical conditions, such as Type II Diabetes and hypertension, which may have a greater impact on the patient's overall health.", "metadata": {"model": "llama"}}
{"query-id": "3", "query-text": "Meningioma NF2 (K322), AKT1(E17K) 45-year-old female None", "response": "Meningioma NF2: A benign tumor arising from the meninges, typically slow-growing & non-invasive. AKT1(E17K): A mutation in the AKT1 gene that can lead to cancer. 45-year-old female: A woman in her mid-40s.", "metadata": {"model": "llama"}}
{"query-id": "4", "query-text": "Breast cancer FGFR1 Amplification, PTEN (Q171) 67-year-old female Depression, Hypertension, Heart Disease", "response": "The patient's FGFR1 amplification and loss of PTEN mutation increase her risk for developing cancer, particularly breast cancer. At 67 years old, she is at higher risk for developing hypertension and heart disease.", "metadata": {"model": "llama"}}
{"query-id": "5", "query-text": "Melanoma BRAF (V600E), CDKN2A Deletion 45-year-old female None", "response": "The prognosis for a 45-year-old female patient with Melanoma BRAF (V600E) and CDKN2A Deletion is generally poor. Without treatment, the cancer is likely to progress and grow, and the patient may experience a poor quality of life and reduced life expectancy. Best treatment options may include clinical trials for new targeted therapies or immunotherapies, or chemotherapy and targeted therapies in combination.", "metadata": {"model": "llama"}}
{"query-id": "6", "query-text": "Melanoma NRAS (Q61K) 55-year-old male Hypertension", "response": "The most likely cancer site for a 55-year-old male patient with hypertension and the NF1 mutation (Q61K) is melanoma.", "metadata": {"model": "llama"}}
{"query-id": "7", "query-text": "Lung cancer EGFR (L858R) 50-year-old female Lupus", "response": "Lung cancer patient (50-year-old female) with L858R EGFR mutation and a history of Lupus. Targeted therapy options include gefitinib, erlotinib, and afatinib.", "metadata": {"model": "llama"}}
{"query-id": "8", "query-text": "Lung cancer EML4-ALK Fusion transcript 52-year-old male Hypertension, Osteoarthritis", "response": "The EML4-ALK fusion transcript is detected in the lung cancer tissue of a 52-year-old male with a history of hypertension and osteoarthritis.", "metadata": {"model": "llama"}}
{"query-id": "9", "query-text": "Gastrointestinal stromal tumor KIT Exon 9 (A502_Y503dup) 49-year-old female None", "response": "The KIT Exon 9 (A502_Y503dup) mutation in a 49-year-old female patient with a gastrointestinal stromal tumor is typically associated with a worse prognosis. This mutation leads to an activating signal in the tumor cells, promoting cell growth and proliferation. Treatment options may include surgery, chemotherapy, and targeted therapy with KIT inhibitors.", "metadata": {"model": "llama"}}
{"query-id": "10", "query-text": "Lung adenocarcinoma KRAS (G12C) 61-year-old female Hypertension, Hypercholesterolemia", "response": "The patient's KRAS (G12C) mutation is relatively common in non-small cell lung cancer (NSCLC) and is associated with resistance to EGFR tyrosine kinase inhibitors. As the patient is 61 years old and has a history of hypertension and hypercholesterolemia, further investigation and management of these comorbidities are necessary to optimize her overall health before considering treatment for the lung cancer.", "metadata": {"model": "llama"}}
{"query-id": "11", "query-text": "Gastric cancer PIK3CA (E545K) 54-year-old male Depression", "response": "The PIK3CA (E545K) mutation in a 54-year-old male with gastric cancer may be associated with an increased risk of depression. Studies have shown that patients with gastric cancer harboring this mutation tend to have a worse prognosis and higher rates of depression compared to those without the mutation.", "metadata": {"model": "llama"}}
{"query-id": "12", "query-text": "Colon cancer BRAF (V600E) 35-year-old male None", "response": "BRAFmutation in colon cancer: The patient is eligible for targeted therapy with dabrafenib or vemurafenib, which are BRAF inhibitors that have shown efficacy in KRAS mutant cancers with V600E mutations.", "metadata": {"model": "llama"}}
{"query-id": "13", "query-text": "Cholangiocarcinoma BRCA2 72-year-old male Diabetes", "response": "Yes, there is an increased risk of cholangiocarcinoma (bile duct cancer) for a 72-year-old male with a history of diabetes. Studies have shown that individuals with diabetes have a higher risk of developing cholangiocarcinoma, particularly in the setting of chronic inflammation and obstructive pancreatitis.", "metadata": {"model": "llama"}}
{"query-id": "14", "query-text": "Cholangiocarcinoma IDH1 (R132H) 64-year-old male Neuropathy", "response": "The IDH1 R132H mutation is a common mutation seen in cholangiocarcinoma, particularly in intrahepatic cholangiocarcinoma. It is associated with aggressive disease and poor prognosis. Neuropathy is a common symptom in cholangiocarcinoma patients, particularly those with advanced disease.", "metadata": {"model": "llama"}}
{"query-id": "15", "query-text": "Cervical cancer STK11 26-year-old female None", "response": "The 26-year-old female patient does not have the STK11 mutation, which is commonly associated with cervical cancer.", "metadata": {"model": "llama"}}
{"query-id": "16", "query-text": "Pancreatic cancer CDKN2A 54-year-old male Diabetes, Hypertension", "response": "The CDKN2A gene mutation is present in 30% of pancreatic cancers, including in the 54-year-old male with diabetes and hypertension.", "metadata": {"model": "llama"}}
{"query-id": "17", "query-text": "Prostate cancer PTEN Inactivating 81-year-old male Hypertension, Depression", "response": "The presence of PTEN inactivating mutations in an 81-year-old male with hypertension and depression may increase the risk of prostate cancer.", "metadata": {"model": "llama"}}
{"query-id": "18", "query-text": "Pancreatic cancer CDK6 Amplification 48-year-old male None", "response": "CDK6 amplification is present in 30-40% of pancreatic cancers, including those in 48-year-old males. It can lead to increased cell growth and proliferation, and may be associated with poor prognosis.", "metadata": {"model": "llama"}}
{"query-id": "19", "query-text": "Colorectal cancer FGFR1 Amplification 35-year-old female None", "response": "FGFR1 amplification is present in 10-30% of colorectal cancers, including those in 35-year-old females.", "metadata": {"model": "llama"}}
{"query-id": "20", "query-text": "Liposarcoma MDM2 Amplification 26-year-old male None", "response": "Liposarcoma with MDM2 amplification in a 26-year-old male patient is a rare and aggressive soft tissue sarcoma. Treatment options may include surgery, radiation therapy, and chemotherapy. Prognosis is generally poor, with a 5-year survival rate of approximately 40%.", "metadata": {"model": "llama"}}
{"query-id": "21", "query-text": "Lung adenocarcinoma ALK Fusion 64-year-old female Emphysema", "response": "The ALK fusion gene is a known driver mutation in non-small cell lung cancer (NSCLC) and is detected in approximately 5-7% of NSCLC cases. A 64-year-old female patient with a history of emphysema is at increased risk of developing ALK-positive lung adenocarcinoma, and further testing with an ALK reverse transcription polymerase chain reaction (RT-PCR) or next-generation sequencing (NGS) can confirm the diagnosis.", "metadata": {"model": "llama"}}
{"query-id": "22", "query-text": "Lung cancer ERBB2 Amplification 70-year-old male Arthritis", "response": "Yes, ERBB2 amplification has been found to be associated with aggressive pulmonary adenocarcinoma in non-small cell lung cancer (NSCLC) in elderly patients, including 70-year-old males with arthritis.", "metadata": {"model": "llama"}}
{"query-id": "23", "query-text": "Breast cancer PTEN Loss 54-year-old female Congestive Heart Failure", "response": "Treatment for breast cancer with PTEN loss in a 54-year-old female with congestive heart failure may involve chemotherapy, hormone therapy, or targeted therapy with drugs like trametinib or umbralisib, which have shown activity against PTEN-mutated breast cancers.", "metadata": {"model": "llama"}}
{"query-id": "24", "query-text": "Lung cancer NTRK1 58-year-old female Depression, Hypertension, Diabetes", "response": "Based on the patient's history of depression, hypertension, and diabetes, the likelihood of NTRK1 lung cancer is low. These comorbidities are more commonly associated with other types of cancer, such as breast, colon, or prostate cancer. However, further investigation with imaging studies and biopsy may be warranted to confirm the absence of lung cancer.", "metadata": {"model": "llama"}}
{"query-id": "25", "query-text": "Lung adenocarcinoma MET Amplification 48-year-old male Emphysema", "response": "The male patient's lung adenocarcinoma has a MET amplification, which is a gene mutation that is associated with aggressive disease and poor prognosis. The patient is 48 years old and has a history of emphysema, further increasing the risk of developing lung cancer.", "metadata": {"model": "llama"}}
{"query-id": "26", "query-text": "Breast cancer NRAS Amplification 35-year-old female None", "response": "Sure! Here is the answer to the query in 50 words or less:\nBreast cancer NRAS amplification is rarely seen in 35-year-old females without a strong clinical history.", "metadata": {"model": "llama"}}
{"query-id": "27", "query-text": "Pancreatic adenocarcinoma KRAS, TP53 49-year-old female None", "response": "KRAS and TP53 mutations are present in the pancreatic adenocarcinoma of a 49-year-old female patient, increasing the aggressiveness of the disease.", "metadata": {"model": "llama"}}
{"query-id": "28", "query-text": "Pancreatic ductal adenocarcinoma ERBB3 73-year-old female Whipple, FNA", "response": "The ERBB3 protein is overexpressed in Pancreatic Ductal Adenocarcinoma, including in the case of a 73-year-old female patient who underwent a fine needle aspiration biopsy of the tumor (Whipple biopsy).", "metadata": {"model": "llama"}}
{"query-id": "29", "query-text": "Ampullary carcinoma KRAS 61-year-old male None", "response": "KRAS mutation is present in ampullary carcinoma in a 61-year-old male patient, indicating Non-small cell lung cancer (NSCLC) may be present in the nearby tissues.", "metadata": {"model": "llama"}}
{"query-id": "30", "query-text": "Pancreatic adenocarcinoma RB1, TP53, KRAS 57-year-old female None", "response": "The patient's pancreatic adenocarcinoma has mutations in RB1, TP53, and KRAS. She is a 57-year-old female with no prior medical history.", "metadata": {"model": "llama"}}
